GTP 14564 is a cell-permeable tricyclic benzofurano-indazolo compound which functions as a specific inhibitor of class III receptor tyrosine kinases. Studies show that GTP 14564 can be used to track the signaling pathways activated by FLT3 and ITD-FLT3 in Ba/F3 cells. Furthermore, GTP 14564 can suppress the FLT3 internal tandem duplication (ITD) cells to the same extent as FLT3 siRNA. Studies show that if combined with 17-AAG, GTP 14564 can reduce the levels of p-FLT3 and p-STAT5 and can amplify apoptosis and G0/G1 arrest in FLT3-ITD cells. GTP 14564 is an inhibitor of c-Fms-CSF-1R, c-Kit, Flt-3/Flk-2 and PDGFR-beta.
1. Murata, K. et al. 2003. J. Biol. Chem. 278(35): 32892-32898. PMID: 12815052
2. Yao, Q. et al. 2005. Leukemia. 19(9): 1605-1612. PMID: 16034464
See how others have used GTP 14564 (CAS 34823-86-4). Click on the entry to view the PubMed entry .
PMID: # 30426699 Yang, L. et al. 2019. Mol. Plant Pathol. 20: 500-518.
PMID: # 20035824 Jacobi, A. et al. 2010. Exp. Hematol. 38: 180-190.
PMID: # 12815052 Murata, K. et al. 2003. J. Biol. Chem. 278: 32892-32898.
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2020 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.